T-10 represents an innovative synthetic peptide designed as a potent agonist for the glucose-dependent insulinotropic polypeptide (GIP) receptor, incorporating advanced peptide engineering to achieve high activity at this receptor system. The compound consists of a 39-amino acid linear peptide chain with structural similarities to GIP, belonging to the secretin family of gut hormones. The peptide incorporates specific amino acid modifications designed to optimize binding affinity and activation of the target receptor.

The compound features a C20 fatty diacid modification that significantly enhances stability and extends half-life through albumin binding, similar to other long-acting peptide therapeutics. This modification allows for sustained biological activity and makes T-10 suitable for research protocols requiring prolonged GIP receptor activation. The receptor activity profile provides unique opportunities for investigating the effects of GIP signaling pathways in metabolic regulation.

T-10 functions through the activation of GIP receptors, leading to signaling cascades that influence glucose homeostasis, insulin secretion, and metabolic regulation. The compound’s mechanism involves activation of adenylyl cyclase at the receptor system, resulting in increased cyclic adenosine monophosphate (cAMP) levels and downstream effects on pancreatic beta cells, adipose tissue, and other metabolically active tissues.

Research applications of T-10 include the investigation of GIP signaling, glucose homeostasis mechanisms, and metabolic regulation pathways. The compound’s receptor activity profile makes it valuable for studying the GIP signaling system and its effects on metabolic function. Research preparations typically utilize 10mg concentrations with appropriate reconstitution and storage protocols to maintain peptide stability and receptor activity.